Neratinib, Fulvestrant, Trastuzumab Combo Aids Metastatic Breast Cancer
By Elana Gotkine HealthDay Reporter
TUESDAY, Nov. 28, 2023 -- For patients with hormone receptor (HR)-positive HER2-mutant metastatic breast cancer (MBC) with progression on cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy, neratinib + fulvestrant + trastuzumab (N + F + T) is beneficial, according to a study published in the October issue of the Annals of Oncology.
Komal Jhaveri, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues reported results from 71 patients with HR-positive HER2-negative MBC with activating HER2 mutations and prior CDK4/6i therapy. Patients received N + F + T or F + T or fulvestrant alone. Those with disease progression on F + T or fulvestrant alone could cross over to N + F + T.
The researchers found that the objective response rate was 39 percent for 57 N + F + T-treated patients, and median progression-free survival was 8.3 months. There were no responses in the F + T or fulvestrant-treated patients, but responses were seen in those crossing over to N + F + T. Patients with ductal and lobular histology, one or more than one HER2 mutations, and co-occurring HER3 mutations had responses. Acquisition of additional HER2 alterations and mutations in genes including PIK3CA were revealed on longitudinal circulating tumor DNA sequencing, enabling further precision targeting and possible re-response.
"This novel combination therapy showed very encouraging results, even in patients who failed several other lines of treatment," coauthor Carlos L. Arteaga, M.D., from UT Southwestern Simmons Comprehensive Cancer Center in Dallas, said in a statement.
Several authors disclosed ties to biopharmaceutical companies, including Puma Biotechnology, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Large Language Models Fall Short in Breast Imaging Classification
FRIDAY, May 10, 2024 -- Large language models (LLMs) appear to fall short in classification of breast imaging, which can have a negative impact on clinical management, according...
Racial, Ethnic Differences Seen in Breast Cancer Treatment Declination
THURSDAY, May 9, 2024 -- For patients with breast cancer, there are racial and ethnic differences in treatment declination, according to a study published online May 9 in JAMA...
Text Message Outreach Can Help Increase Mammogram Completion Rates
MONDAY, May 6, 2024 -- Text messaging women after initial outreach for breast cancer screening increases mammogram completion rates, according to a study published online May 6 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.